LD MICRO is a by-invitation only newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published an annual list of recommended stocks as well as comprehensive reports on select companies throughout the year. LD MICRO concentrates on finding, researching, and investing in companies that are overlooked by institutional investors. It is a non-registered investment advisor.

For more information on the list of presenting companies or to register for the event, please visit http://www.ldmicro.com or call (408) 457-1042

About the Company

Based in North Brunswick, New Jersey, Advaxis is developing proprietary Listeria monocytogenes (Lm) cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis' scientific advisory board. Advaxis is developing attenuated live Lm vaccines that deliver engineered tumor antigens, which stimulate multiple simultaneous immunological mechanisms to fight cancer.

In a recent Advaxis Phase I clinical trial, a live Lm vaccine directed against the tumor-associated antigen HPV-16-E7 was safely administered to fifteen (15) women with recurrent, advanced, metastatic cancer of the cervix. Although this first trial of an Lm vaccine in humans was not designed or powered to prove efficacy, Advaxis believes an efficacy signal was observed that will be further explored in two (2) planned Phase II trials in the US and India in cervical cancer and its predecessor condition, cervical intraepithelial neoplasia (CIN). Advaxis now has nine (9) distinct cancer fighting constructs in various stages of development, both directly and with academic collaborators. For further information on the Company, please visit: www.advaxis.com.

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.

SOURCE: Advaxis, Inc.

Advaxis, Incorporated 
Conrad Mir, Director, Business Development 
732-545-1590 (Office) 
732-545-1084 (FAX) 
info@advaxis.com 
www.advaxis.com

Duignan was the chief financial officer of Enliven Marketing Technologies Corp. (NASDAQ: ENLV) from November 2006 until the company was sold in October 2008. Duignan worked for Enliven Marketing Technologies Corp. from January 2002 to November 2008, during which time he served as assistant controller, controller, chief accounting officer and chief financial officer. Prior to Enliven Marketing Technologies Corp., Duignan worked at PricewaterhouseCoopers LLP from September 1997 to October 2001 in their technology group within the audit practice. Duignan received a B.S. in Accounting from Fairfield University in 1997 and is a certified public accountant.

Based in North Brunswick, New Jersey, Advaxis is developing proprietary Listeria monocytogenes cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis' scientific advisory board. Advaxis is developing attenuated live Lm vaccines that deliver engineered tumor antigens, which stimulate multiple simultaneous immunological mechanisms to fight cancer.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

http://www.financialwire.net

Based in North Brunswick, New Jersey, Advaxis is developing proprietary Listeria monocytogenes (Lm) cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis' scientific advisory board. Advaxis is developing attenuated live Lm vaccines that deliver engineered tumor antigens, which stimulate multiple simultaneous immunological mechanisms to fight cancer.

In a recent Advaxis Phase I clinical trial, a live Lm vaccine directed against the tumor-associated antigen HPV-16-E7 was safely administered to fifteen (15) women with advanced metastatic cancer of the cervix. Although this first trial of an Lm vaccine in humans was not designed or powered to prove efficacy, Advaxis believes an efficacy signal was observed that will be further explored in two (2) planned Phase II trials in the US and India in cervical cancer and its predecessor condition, cervical intraepithelial neoplasia (CIN). Advaxis now has nine (9) distinct cancer fighting constructs in various stages of development, both directly and with academic collaborators. For further information on the Company, please visit: www.advaxis.com.

About Stonegate Securities

Stonegate is a 30-year old broker/dealer headquartered in Dallas, Texas. We specialize in raising capital and moving large blocks of stock with institutional investors for companies with market capitalizations under $500 million.

About the Relationship between the Company and Stonegate Securities

Advaxis engaged Stonegate Securities ("Stonegate") in June 2009 to act as its non-exclusive placement agent on a "best-efforts" basis in connection with one or more private placements of Advaxis equity and/or debt securities, and provide research distribution services. As compensation for such services, the Company is contracted to pay Stonegate $100,000 and a fee of seven percent (7%) of the gross proceeds from the sale of Advaxis securities to investors, identified by Stonegate; and agreed to reimburse Stonegate for out-of-pocket expenses and issue additional shares of Advaxis stock equal to three percent (3%) of the total number of securities issued in any private placement in which Stonegate participates. Moreover, Advaxis has agreed to indemnify Stonegate for certain liabilities, including liabilities under the Securities Act of 1933 as amended (the "Securities Act").

Shares of the Company's stock, issued and issuable under the aforementioned engagement, have not been registered under the Securities Act. Accordingly, these securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.

SOURCE: Advaxis, Inc.

Advaxis, Incorporated 
Conrad Mir, 732-545-1590 
Director, Business Development 
Fax: 732-545-1084 
info@advaxis.com 
www.advaxis.com

Advaxis said that in this Phase II clinical trial, patients will receive three (3) administrations of ADXS11-001 at monthly intervals. Six (6) months after receiving their first dose, they will receive the standard of care for the treatment of their disease, which is surgery. Efficacy will be determined by comparing pre-treatment biopsy samples with surgical tissue samples. General observations to be made in the trial include that of patients' health and well being, progression and state of disease, and clinical immunology.

The experimental protocol calls for thirty (30) patients in each group to be treated, for a total of one hundred, twenty (120) patients. ADXS11-001 dosage groups include two (2) doses that are lower than previously administered (5.0 x107 and 3.3 x108 cfu) and one at the lowest dose administered in Phase I (1.0x109 cfu).

New England IRB is an independent institutional review board for sponsors, CROs and individual researchers across the U.S. Its priority is to ensure safety of human subjects in clinical trials and we are committed to an ethical and thorough review process. Its Boards are comprised of highly qualified members with significant experience and knowledge in the ethical, scientific and legal aspects of clinical trials.

((Comments on this story may be sent to newsdesk@closeupmedia.com))